N Atluri1, S M Joksimovic1, A Oklopcic2, D Milanovic3, J Klawitter1, P Eggan1, K Krishnan4, D F Covey5, S M Todorovic6, V Jevtovic-Todorovic7. 1. Department of Anaesthesiology, University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, CO, USA. 2. School of Nursing, University of Virginia, Charlottesville, VA, USA. 3. Institute for Biological Research, Department of Neurobiology, University of Belgrade, Belgrade, Serbia. 4. Department of Developmental Biology, Washington University School of Medicine, Saint Louis, MO, USA. 5. Department of Developmental Biology, Washington University School of Medicine, Saint Louis, MO, USA; Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, Saint Louis, MO, USA. 6. Department of Anaesthesiology, University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, CO, USA; Neuroscience Graduate Program, University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, CO, USA. 7. Department of Anaesthesiology, University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, CO, USA. Electronic address: vesna.jevtovic-todorovic@ucdenver.edu.
Abstract
BACKGROUND: More than 4 million children are exposed annually to sedatives and general anaesthetics (GAs) in the USA alone. Recent data suggest that common GAs can be detrimental to brain development causing neurodegeneration and long-term cognitive impairments. Challenged by a recent US Food and Drug Administration (FDA) warning about potentially neurotoxic effects of GAs in children, there is an urgent need to develop safer GAs. METHODS: Postnatal Day 7 (P7) rat pups of both sexes were exposed to six (repeated every 2 h) injections of equipotent hypnotic doses of ketamine or the neuroactive steroid (3β,5β,17β)-3-hydroxyandrostane-17-carbonitrile (3β-OH) for 12 h. Loss of righting reflex was used to assess hypnotic properties and therapeutic index; quantitative caspase-3 immunohistochemistry was used to assess developmental neuroapoptosis; patch-clamp recordings in acute brain slices were used to assess the effects of 3β-OH on neuronal excitability and synaptic transmission. Cognitive abilities of rats exposed to ketamine, 3β-OH, or vehicle at P7 were assessed in young adulthood using the radial arm maze. RESULTS: The neuroactive steroid 3β-OH has a therapeutic index similar to ketamine, a commonly used clinical GA. We report that 3β-OH is safe and, unlike ketamine, does not cause neuroapoptosis or impair cognitive development when administered to P7 rat pups. Interestingly, 3β-OH blocks T-type calcium channels and presynaptically dampens synaptic transmission at hypnotically-relevant brain concentrations, but it lacks a direct effect on γ-aminobutyric acid A or glutamate-gated ion channels. CONCLUSIONS: The neurosteroid 3β-OH is a relatively safe hypnotic that warrants further consideration for paediatric anaesthesia.
BACKGROUND: More than 4 million children are exposed annually to sedatives and general anaesthetics (GAs) in the USA alone. Recent data suggest that common GAs can be detrimental to brain development causing neurodegeneration and long-term cognitive impairments. Challenged by a recent US Food and Drug Administration (FDA) warning about potentially neurotoxic effects of GAs in children, there is an urgent need to develop safer GAs. METHODS: Postnatal Day 7 (P7) rat pups of both sexes were exposed to six (repeated every 2 h) injections of equipotent hypnotic doses of ketamine or the neuroactive steroid (3β,5β,17β)-3-hydroxyandrostane-17-carbonitrile (3β-OH) for 12 h. Loss of righting reflex was used to assess hypnotic properties and therapeutic index; quantitative caspase-3 immunohistochemistry was used to assess developmental neuroapoptosis; patch-clamp recordings in acute brain slices were used to assess the effects of 3β-OH on neuronal excitability and synaptic transmission. Cognitive abilities of rats exposed to ketamine, 3β-OH, or vehicle at P7 were assessed in young adulthood using the radial arm maze. RESULTS: The neuroactive steroid 3β-OH has a therapeutic index similar to ketamine, a commonly used clinical GA. We report that 3β-OH is safe and, unlike ketamine, does not cause neuroapoptosis or impair cognitive development when administered to P7 rat pups. Interestingly, 3β-OH blocks T-type calcium channels and presynaptically dampens synaptic transmission at hypnotically-relevant brain concentrations, but it lacks a direct effect on γ-aminobutyric acid A or glutamate-gated ion channels. CONCLUSIONS: The neurosteroid 3β-OH is a relatively safe hypnotic that warrants further consideration for paediatric anaesthesia.
Authors: Hong-Jin Shu; Lawrence N Eisenman; Deepani Jinadasa; Douglas F Covey; Charles F Zorumski; Steven Mennerick Journal: J Neurosci Date: 2004-07-28 Impact factor: 6.167
Authors: Katie J Schenning; Kevin K Noguchi; Lauren Drew Martin; Francesca M Manzella; Omar H Cabrera; Gregory A Dissen; Ansgar M Brambrink Journal: Neurotoxicol Teratol Date: 2016-11-19 Impact factor: 3.763
Authors: Ansgar M Brambrink; Alex S Evers; Michael S Avidan; Nuri B Farber; Derek J Smith; Xuezhao Zhang; Gregory A Dissen; Catherine E Creeley; John W Olney Journal: Anesthesiology Date: 2010-04 Impact factor: 7.892
Authors: Mariangela Chisari; Lawrence N Eisenman; Kathiresan Krishnan; Achintya K Bandyopadhyaya; Cunde Wang; Amanda Taylor; Ann Benz; Douglas F Covey; Charles F Zorumski; Steven Mennerick Journal: J Neurophysiol Date: 2009-06-24 Impact factor: 2.714
Authors: Janelle R Latham; Sriyani Pathirathna; Miljen M Jagodic; Won Joo Choe; Michaela E Levin; Michael T Nelson; Woo Yong Lee; Kathiresan Krishnan; Douglas F Covey; Slobodan M Todorovic; Vesna Jevtovic-Todorovic Journal: Diabetes Date: 2009-08-03 Impact factor: 9.461
Authors: Francesca M Manzella; Douglas F Covey; Vesna Jevtovic-Todorovic; Slobodan M Todorovic Journal: J Neuroendocrinol Date: 2022-01-10 Impact factor: 3.627
Authors: Sonja L Joksimovic; Douglas F Covey; Vesna Jevtovic-Todorovic; Slobodan M Todorovic Journal: Front Pharmacol Date: 2018-10-02 Impact factor: 5.810